BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• BioMidwest

  Merck Animal Health Announces Increase in Funding for Veterinary Student Scholarship Program

  Merck Animal Health has announced an increase of $115,000 in funding for its Veterinary Student Scholarship Program.

  November 13, 2017

   · 

  3 min read
• 

  Drug Development

  Amgen’s New Analyses Show Repatha Significantly Reduced Cardiovascular Events in Patients With Peripheral Artery Disease and in Patients With a History of Heart Attacks

  These results highlight Repatha’s ability to reduce the residual risk for CV events particularly in high-risk patients with limited treatment options.

  November 13, 2017

   · 

  18 min read
• Business

  Orexigen Therapeutics Announces Third Quarter 2017 Financial Results

  Total operating expenses for the third quarter of 2017 were $37.6M compared to a credit of $37.5M for the third quarter of 2016.

  November 13, 2017

   · 

  24 min read
• BioCapital

  QIAGEN Celebrates Surpassing 2,000 Cumulative Placements of QIAsymphony

  QIAGEN N.V. today announced the 2,000th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories worldwide.

  November 13, 2017

   · 

  1 min read
• Business

  Yew Bio-Pharm Group Reports 2017 Third Quarter Financial Results

  For the 2017 third quarter, gross profit was $749,916, or 6.5% of total revenues, compared with $1.4M, or 9.7% of total revenues for the comparable 2016 quarter.

  November 13, 2017

   · 

  32 min read
• Business

  Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017

  R&D expenses for the quarter ended September 30, 2017 were$24.4M, compared to $3.8M for the comparable period in 2016.

  November 13, 2017

   · 

  16 min read
• Business

  Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results

  Alpine ended the third quarter of 2017 with $87.2 million in cash, cash equivalents, and short-term investments compared to $11.8 million as of December 31, 2016.

  November 13, 2017

   · 

  9 min read
• Genetown

  Myomo Files Registration Statement for Proposed Follow-On Offering

  Myomo, a commercial stage medical robotics company, announced the filing of a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten follow-on public offering of shares of its common stock and accompanying warrants to purchase common stock.

  November 13, 2017

   · 

  3 min read
• Business

  Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress

  As of September 30, 2017, Synlogic had cash, cash equivalents, and short-term investments of $96.6 million.

  November 13, 2017

   · 

  9 min read
• Business

  Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017

  As of September 30, 2017, Cellectis had $304.1 million in total cash, cash equivalents and current financial assets compared to $271.2 million as of June 30, 2017.

  November 13, 2017

   · 

  22 min read